The FDA has granted Breakthrough Device status to BioVentrix, Inc.’s Revivent TC Transcatheter Ventricular Enhancement System, a proactive approach to treating MI-induced heart failure.

A new structural heart disease initiative from the American Heart Association and Edwards Lifesciences will aim to raise patient awareness of valve diseases while enriching patient education and engagement.

Nearly one-third of insured adults with diagnosed hypertension were nonadherent to their antihypertensive medications in 2015, according to a report published Nov. 4 in Hypertension.

A novel pacemaker designed to mimic a patient’s organic breath increased blood flow to the heart in a study of individuals with heart failure, according to research published in the journal Thorax.

Patients with heart failure and reduced ejection fraction are well served by treatment with the glucose-lowering drug dapagliflozin, as it warded off death and hospitalization while also improving quality of life when added to standard care regimens in a major trial.

Apple has opted to remove all vaping-related apps from its App Store in the midst of an e-cigarette epidemic that’s fueled more than 2,000 cases of vaping-related lung injury and at least 42 fatalities.

Results of the late-breaking COLCOT trial, which explored the efficacy of low-dose colchicine in reducing CV risk in heart attack patients, were a highlight of the American Heart Association’s 2019 Scientific Sessions this month in Philadelphia.

People with severe but stable ischemic heart disease don’t benefit any more from invasive CV procedures than they do from optimal medical therapy and lifestyle changes alone, according to results from the highly anticipated ISCHEMIA trial.